US20220409544A1 - Stable parenteral formulations of duloxetine - Google Patents
Stable parenteral formulations of duloxetine Download PDFInfo
- Publication number
- US20220409544A1 US20220409544A1 US17/778,906 US202017778906A US2022409544A1 US 20220409544 A1 US20220409544 A1 US 20220409544A1 US 202017778906 A US202017778906 A US 202017778906A US 2022409544 A1 US2022409544 A1 US 2022409544A1
- Authority
- US
- United States
- Prior art keywords
- solution
- duloxetine
- buffer
- formulation
- clear solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 title claims abstract description 126
- 229960002866 duloxetine Drugs 0.000 title claims abstract description 125
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000009472 formulation Methods 0.000 title claims abstract description 64
- 239000000872 buffer Substances 0.000 claims abstract description 62
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 289
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 144
- 239000004471 Glycine Substances 0.000 claims description 72
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 38
- 229930195725 Mannitol Natural products 0.000 claims description 38
- 239000000594 mannitol Substances 0.000 claims description 38
- 235000010355 mannitol Nutrition 0.000 claims description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000008135 aqueous vehicle Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008363 phosphate buffer Substances 0.000 claims description 11
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims description 10
- 239000004067 bulking agent Substances 0.000 claims description 10
- 239000008347 soybean phospholipid Substances 0.000 claims description 10
- 239000008121 dextrose Substances 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 239000008351 acetate buffer Substances 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008362 succinate buffer Substances 0.000 claims description 2
- 239000012931 lyophilized formulation Substances 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 239000008364 bulk solution Substances 0.000 description 68
- 238000004519 manufacturing process Methods 0.000 description 47
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 42
- 238000002360 preparation method Methods 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 229960002885 histidine Drugs 0.000 description 22
- 239000012535 impurity Substances 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 238000011049 filling Methods 0.000 description 14
- 238000004108 freeze drying Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 230000035699 permeability Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229910001220 stainless steel Inorganic materials 0.000 description 12
- 239000010935 stainless steel Substances 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 229910021642 ultra pure water Inorganic materials 0.000 description 11
- 239000012498 ultrapure water Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 229960002496 duloxetine hydrochloride Drugs 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 description 8
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 7
- 230000004907 flux Effects 0.000 description 7
- 229960001031 glucose Drugs 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 239000008156 Ringer's lactate solution Substances 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- FKGDSSDAWPLWAQ-UHFFFAOYSA-N butanedioic acid;sodium Chemical compound [Na].[Na].OC(=O)CCC(O)=O FKGDSSDAWPLWAQ-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960002870 gabapentin Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 3
- 229960001233 pregabalin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229960000673 dextrose monohydrate Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- OJXMJLCWKLPCHB-UHFFFAOYSA-N 4-[3-(methylamino)-1-thiophen-2-ylpropyl]naphthalen-1-ol Chemical compound C=1C=C(O)C2=CC=CC=C2C=1C(CCNC)C1=CC=CS1 OJXMJLCWKLPCHB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- -1 Glycine Acetate Acetate Boric Acid Boric Acid Chemical compound 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004614 Process Aid Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- ZEUITGRIYCTCEM-UHFFFAOYSA-N duloxetine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCNC)C1=CC=CS1 ZEUITGRIYCTCEM-UHFFFAOYSA-N 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229940059096 powder for oral suspension Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the present invention relates to a parenteral dosage form of duloxetine or a pharmaceutically acceptable salt thereof and the method of manufacture of the said dosage form.
- the parenteral dosage form of this invention provides immediate relief to the patients.
- Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), chemically known as (+)—N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propan-1-amine).
- SSNRI serotonin and norepinephrine reuptake inhibitor
- Duloxetine is not stable in presence of acid and degrades rapidly in acidic environment of the gastrointestinal tract.
- One of the degradant of acid hydrolysis is 1-napthol, which is known to be toxic and causes several side effects. To avoid the degradation and side effects, duloxetine is supplied as an enteric coated dosage form.
- Duloxetine is commercially available in USA as delayed release capsules containing enteric coated duloxetine hydrochloride pellets. The product is sold under the brand name Cymbalta®. Duloxetine is used in the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain. The T lag (time for the absorption to begin) of duloxetine is 2 hours and Tmax (time to reach maximum concentration) is 6 to 10 hours. Hence the product is indicated to be administered 2 hours before the surgery for pain management.
- duloxetine is such that quick onset of action is desirable. This is not possible with the currently available enteric coated formulation where the GI transit time is more than 6 hours. Further, the capsule formulation may present difficulties in swallowing in pediatric and elderly patients. This often leads to discontinuation of treatment and poor patient compliance.
- enteric duloxetine pellet formulation comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient; b) an optional separating layer; c) an enteric layer comprising hydroxyl propyl methylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient.
- HPMCAS hydroxyl propyl methylcellulose acetate succinate
- U.S. Pat. No. 8,758,779 discloses duloxetine powder for oral suspension whereas U.S. Pat. Nos. 8,455,667 and 8,513,439 disclose oral liquid compositions comprising duloxetine with suitable buffers. None of these patents have disclosures for making parenteral formulations.
- the prior art formulations are associated with many disadvantages. Some of these are—increased time for absorption and onset of action for the enteric coated formulations, variability in drug absorption in different patients, difficulty in administering the formulations to patients who cannot take oral medication, pediatric and geriatric patients and possible degradation of the drug due to increased time of contact with gastric acids.
- the present invention relates to a parenteral formulation of duloxetine comprising duloxetine dissolved in a suitable solvent system comprising one or more buffers, stabilizers and other pharmaceutically acceptable excipients.
- the formulation is in the form of a lyophilized injection comprising duloxetine.
- FIG. 01 shows Permiability of various formulations evaluated using Rat Intestine at 15 minutes time (mcg/cm 2 ).
- duloxetine is intended to refer to the pharmaceutically acceptable salts, solvates and polymorphs thereof. Duloxetine Hydrochloride is most preferred.
- Water Content in the pharmaceutical formulation plays a major role in degrading the product. Drug gets degraded when it comes in contact with water, which ultimately effects the self-life of the product.
- the term “Water Content” in the present invention refers to an amount less than 5% w/w and more preferably less than 3% w/w even after 6 months of storage at accelerated conditions.
- Water Content and Moisture Content are interchangeable and means the same throughout the specification.
- lyophilize in the context of this invention, is intended to refer to the process of freeze drying of a solution comprising duloxetine and other pharmaceutically acceptable excipients.
- lyophilizate refers to the product of lyophilization.
- substitution refers to dissolution of the lyophilizate for achieving a solution.
- parenteral formulation means a pharmaceutical formulation that can be administered through intravenous, intramuscular, subcutaneous, intraperitoneal and intrathecal routes of administration.
- the present invention relates to a parenteral formulation of duloxetine for preoperative, peri-operative, post-operative pain management to reduce or alleviate need for Opioids and, therefore, opioid-related adverse effects or opioid-induced hyperalgesia, and for management of chronic and acute painful conditions.
- the present inventors have now surprisingly found that it is possible to make a duloxetine lyophilized formulation that would overcome the disadvantages associated with prior art.
- the invention encompasses a lyophilized parenteral formulation of duloxetine.
- Lyophilization or freeze-drying is a method for dehydrating samples used to preserve or increase stability or to stop degradation. Due to the low water content of lyophilized products, the action of microorganisms and enzymes is inhibited and the product life thereby increased.
- lyophilization the sample to be lyophilized is dissolved in an aqueous solution and subsequently frozen after which the surrounding pressure is reduced. The sample is then submitted to sublimation, optionally by the application of heat, in order to sublime the frozen water directly from the solid phase to the gas phase.
- the lyophilized parenteral formulation of this invention comprises duloxetine dissolved in an aqueous vehicle and subsequently lyophilized in appropriate containers or glass vials.
- the lyophilizate thus formed can be reconstituted with a normal physiological solution like normal saline or with a specific diluent.
- the aqueous vehicle is preferably a sterile aqueous vehicle that is normally used as liquid vehicle for injection.
- Suitable aqueous vehicles include, for example, sterile water and sterile aqueous vehicles that contain suitable excipients that promote and preserve the stability of duloxetine after reconstitution.
- the invention in another embodiment, relates to a lyophilized formulation comprising (i) duloxetine (ii) a bulking agent, (iii) an aqueous vehicle and (iv) other pharmaceutically acceptable excipients.
- Bulking agents are used in lyophilization to increase product mass, adjust tonicity, improve product appearance, prevent product collapse, or aid in rehydration.
- Bulking agents for the purpose of this invention may be selected from mannitol, dextrose, cyclodextrin, sodium chloride, sorbitol and the like. Mannitol is the most preferred.
- the bulking agents may make up 1-99% by weight of the lyophilized solid.
- the aqueous vehicle can be selected from one or more of buffers selected from the group comprising acetate buffer, phosphate buffer, aspartic acid and boric acid buffer, citrate buffer and glycine buffer, succinate buffer, alanine buffer, valine buffer, histidine buffer, lactic acid buffer and the like.
- the aqueous vehicle can also contain mixture of process aid solvents like alcohols, acetonitrile, acetone and like that are removed during lyophilization.
- the inventors carried out solubility/solution stability studies to determine the solution solubility of duloxetine in various buffers at different pH values.
- the concentration of the solution was kept at 10 mg/ml,
- the samples were stored for 24 hours and analyzed for pH, assay and total impurities by standard analytical procedures.
- the data showed that duloxetine has satisfactory stability in all the buffers tested.
- the acetate buffer at pH-5.5 and pH-6.4 and the glycine buffer at pH-5.5 and pH-6.4 showed best results in terms of assay and total impurities.
- the invention relates to a lyophilized formulation comprising (i) duloxetine, (ii) a bulking agent, (iii) an aqueous vehicle, (iv) a stabilizer and (v) other pharmaceutically acceptable excipients.
- the invention relates to a lyophilized formulation comprising (i) duloxetine, (ii) a bulking agent (iii) an aqueous vehicle, (iv) a stabilizer, (v) one or more pH adjusting agents and (vi) other pharmaceutically acceptable excipients.
- the invention relates to a lyophilized formulation comprising (i) duloxetine, (ii) a bulking agent (iii) an aqueous vehicle, (iv) a stabilizer, (v) one or more surfactants and (vi) other pharmaceutically acceptable excipients.
- the lyophilized formulation of the present invention has less than 0.5% w/w of each of the following impurities: duloxetine 4-napthyl isomer ((4-[3-(Methylamino)-1-(thiophen-2-yl)propyl]naphthalen-1-ol), alpha napthol ((Naphthalen-1-01)), duloxetine beta napthol-1-yl isomer ((2-[3-(Methylamino)-1-(thiophen-2-yl)propyl]naphthalen-1-01)). More specifically the above said impurities are less than 0.3% w/w each, even after 6 months of storage under accelerated conditions.
- the stabilizer in the formulation can be selected from one or more of DOTA, DTPA, EDTA and the like.
- the quantity of the stabilizer can be from 0.001% w/w to 10% w/w.
- the one or more pH adjusting agents can be selected from the group comprising sodium hydroxide, hydrochloric acid, mineral acids, carboxylic acids and salts thereof.
- the surfactants may be selected from the group comprising lecithin, soya lecithin, egg lecithin, PEG-PE, phosphatidyl choline, etc
- the invention relates to a kit comprising lyophilized formulation of duloxetine supplied together with a diluent.
- the diluent supplied in the kit can be selected from water for injection, dextrose solution, normal saline, mannitol solution, dextrose normal saline solution (DNS), half saline solution (with a concentration of sodium chloride at 0.45% w/v), dextrose 5%, Normal saline with Arginine (pH 10.07), Ringer Lactate solution.
- the lyophilized formulation of the present invention can be reconstituted with the diluent solution described above. It can be administered directly after reconstitution or may further be diluted with any of the physiologically acceptable solutions at the time of administration.
- the lyophilized samples prepared as per the invention were reconstituted with water and normal saline.
- the subject-matter of the present invention further relates to a process for preparing the lyophilized formulation and the kit.
- the process comprises the steps of:
- duloxetine or a pharmaceutically acceptable salt or solvates thereof (i) mixing the following components (in any suitable order): duloxetine or a pharmaceutically acceptable salt or solvates thereof; an aqueous vehicle; one or more bulking agents; optionally one or more stabilizers; and optionally one or more pH adjusting agents; to provide for an aqueous preparation, wherein duloxetine has a concentration of 1 to 20% w/v, based on the aqueous preparation;
- the aqueous preparation may be a suspension/dispersion or solution.
- the lyophilization step may be carried out in vials, blisters or in any other larger vessel, such as stainless-steel trays or tanks, called “bulk lyophilization”.
- step (i) The bulk solution prepared in step (i) was evaluated for stability. The data is tabulated below. Stability of bulk solution is important to ensure a quality product even in the case unforeseen prolonged process times. Various concentrations of the drug i.e 10 mg/ml, 20 mg/ml and 30 mg/ml were studied in different pH ranges. The formulations were prepared as per the details of example 1.
- permeability of drug from the formulation plays a significant role.
- various formulations were evaluated for permeability flux rate of Duloxetine using invitro ex-vivo rat intestine.
- Wistar Rats of Body weight of 300 (+25) grams were selected and fasted overnight for 12 hours before sacrificing.
- the animals were sacrificed by cervical dislocation and intestinal segments (jejunum portion) were isolated.
- the isolated intestine segments were washed with Ringer lactate solution then stored in aerated Ringer solution till usage. 20 cms of intestine segment was selected to fill 2 mL of the sample. Both the ends of the segments were tied with cotton thread ensuring no leakage from the surface and subjected for diffusion study for determining permeability.
- examples of 8A, 16, 17, 6 and 18 were diluted to get concentration of 5 mg/mL of duloxetine in phosphate buffer pH 6.8. 2 mL of each solution was taken in separate.
- Diffusion study was performed by placing the intestine segments in 50 mL of oxygenated 6.8 pH phosphate buffer at 37 ⁇ 0.5° C. temperature under rotary shaking at 50 rpm.
- the intestine acts as donor chamber and diffusion media acts as receptor chamber from which aliquot samples were collected at predefined time points.
- the sample were collected at 15 mins, 30 mins, 45 mins, 1 Hrs, 2 Hrs, 3 Hrs, 6 Hrs, 12 Hrs, 24 Hrs and 48 Hrs. At each time point 1 mL of the sample was collected from the diffusion phase and replaced with equal volume of phosphate buffer of temperature 37 ⁇ 0.5° C. temperature. The samples were analysed using HPLC method for Duloxetine content.
- the samples collected at each time point were analysed for diffused drug content by HPLC method.
- the flux rates were calculated from slope of a trend-line plotted by taking cumulative amount drug release form unit surface area (i.e. mcg/cm2) against time (h).
- the flux rates were calculated using the following equation
- J is the Flux of compound “m” moving through a cross-sectional area “A” during time “t”
- FIG. number 1 illustrates Permeability of various formulations evaluated using Rat Intestine at 15 minutes time (mcg/cm2).
- the permeability flux rate of duloxetine formulation containing Lecithin's or PEG-PE or Cyclodextrin was found to be increased by 2-3 folds than compared to flux rates of drug solution that does not have any of these excipients.
- Multimodal analgesia or “balanced analgesia” for the treatment of postoperative pain management.
- Multimodal or Balanced Analgesia includes involves the use of more than one method or modality of controlling pain (e.g., drugs from two or more classes, drug plus nondrug treatment) to obtain additive beneficial effects, reduce side effects, or both.
- the invention also encompasses an injection formulation comprising (i) duloxetine or a pharmaceutically acceptable salt thereof, and (ii) a second active ingredient, selected from the group comprising paracetamol, diclofenac, gabapentin, pregabalin, dexamethasone, lidocaine, melatonin etc.
- the pH of the bulk solution is adjusted by using 5.0N Sodium hydroxide solution.
- the bulk solution is filled into vials and lyophilized.
- the bulk solution is filled into vials and lyophilized.
- Example 3A Example 3B Example 3C Qty/ Qty Qty/ Qty Qty/ Qty vial % Vial % vial % S. No Ingredients (mg) w/v (mg) w/v (mg) w/v 1.
- DOTA* 0.15 0.02 0.3 0.02 0.45 0.02 4.
- Acetate buffer Q.s to 87.08 Q.s to 87.08 Q.s to 87.08 (20 mg/mL) 0.75 mL 1.5 mL 2.25 mL *DOTA—Dodecane tetra acetic acid
- the pH of the bulk solution was adjusted to 5.5 by using 5N Sodium hydroxide solution.
- the pH of the bulk solution was adjusted to 5.5 by using 5N Sodium hydroxide solution.
- the pH of the bulk solution was adjusted to 5.5 by using 5N Sodium hydroxide solution.
- pH of the above bulk solution was adjusted to pH 6.0 ⁇ 0.1 using L-histidine.
- pH of the above bulk solution was adjusted to pH 6.0 ⁇ 0.1 using disodium succinic acid.
- Example 8A Example 8 B Qty Qty Qty Qty Qty Qty Qty Qty S. No Ingredients (mg/mL) % w/v % w/w (mg/mL) % w/v % w/w 1. Duloxetine 30.00 3.00 31.40 30.0 3.0 30.86 Hydrochloride 2. Mannitol 45.00 4.50 47.10 45.0 4.50 46.29 3. EDTA 0.20 0.02 0.20 0.20 0.02 0.205 4. Soy lecithin 10.00 1.00 10.468 10.0 1.00 10.28 (Lipoid S 100) 5. L-Histidine 0.32 0.03 0.34 — — — 6.
- pH of the above bulk solution was adjusted to pH 6.0 ⁇ 0.1 using L-histidine.
- pH of the above bulk solution was adjusted to pH 6.0 ⁇ 0.1 using disodium succinate.
- pH of the above bulk solution was adjusted to pH 6.5 ⁇ 0.1 using L-histidine.
- duloxetine To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of gabapentin and stirred well for 15 minutes at 400 rpm until a clear solution is obtained.
- pH of the above bulk solution was adjusted to pH 6.5 ⁇ 0.1 using L-histidine.
- Example 11A Example 11B Qty Qty Qty Qty Qty Qty Qty Qty Qty Qty Qty Qty Qty (mg/ (mg/ % % (mg/ (mg/ % % S. No Ingredients 20 mL) mL) w/v w/w 20 mL) mL) w/v w/w 1. Duloxetine 30.00 1.50 0.30 2.66 30.00 1.50 0.30 3.22 Hydrochloride 2. Dexamethasone 8.00 0.40 0.08 0.711 12.00 0.60 0.12 1.29 sodium phosphate 3. Mannitol 875.00 43.75 4.37 77.74 875.00 43.75 4.37 94.10 4.
- pH of the above bulk solution was adjusted to pH 6.5 ⁇ 0.1 using L-histidine.
- pH of the above bulk solution was adjusted to pH 6.0 ⁇ 0.1 using L-histidine.
- pH of the above bulk solution was adjusted to pH 6.0 ⁇ 0.1 using L-histidine.
- pH of the above bulk solution was adjusted to pH 6.0 ⁇ 0.1 using disodium succinic acid.
- Example 18 Compositions of Duloxetine API Solution Prepared in Phosphate Buffer pH 6.4 (Used as Control in the Study)
Abstract
The present invention relates to a parenteral lyophilized formulation of duloxetine or a pharmaceutically acceptable salt thereof. Further, this invention relates to duloxetine dissolved in a suitable solvent system comprising one or more buffers, stabilizers, and other pharmaceutically acceptable excipients and subsequently lyophilized. The invention also describes combination formulation of Duloxetine with other active ingredients.
Description
- The present invention relates to a parenteral dosage form of duloxetine or a pharmaceutically acceptable salt thereof and the method of manufacture of the said dosage form. The parenteral dosage form of this invention provides immediate relief to the patients.
- Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), chemically known as (+)—N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propan-1-amine). Duloxetine is not stable in presence of acid and degrades rapidly in acidic environment of the gastrointestinal tract. One of the degradant of acid hydrolysis is 1-napthol, which is known to be toxic and causes several side effects. To avoid the degradation and side effects, duloxetine is supplied as an enteric coated dosage form.
- Duloxetine is commercially available in USA as delayed release capsules containing enteric coated duloxetine hydrochloride pellets. The product is sold under the brand name Cymbalta®. Duloxetine is used in the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain. The Tlag (time for the absorption to begin) of duloxetine is 2 hours and Tmax (time to reach maximum concentration) is 6 to 10 hours. Hence the product is indicated to be administered 2 hours before the surgery for pain management.
- The indications of duloxetine are such that quick onset of action is desirable. This is not possible with the currently available enteric coated formulation where the GI transit time is more than 6 hours. Further, the capsule formulation may present difficulties in swallowing in pediatric and elderly patients. This often leads to discontinuation of treatment and poor patient compliance. There are patents describing oral formulations of duloxetine. For eg, U.S. Pat. No. 5,508,276 discloses an enteric duloxetine pellet formulation comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient; b) an optional separating layer; c) an enteric layer comprising hydroxyl propyl methylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient. The patent describes the importance of formulating duloxetine as enteric coated pellets for better absorption and bioavailability but does not talk about parenteral formulations of duloxetine.
- U.S. Pat. No. 8,758,779 discloses duloxetine powder for oral suspension whereas U.S. Pat. Nos. 8,455,667 and 8,513,439 disclose oral liquid compositions comprising duloxetine with suitable buffers. None of these patents have disclosures for making parenteral formulations.
- The prior art formulations are associated with many disadvantages. Some of these are—increased time for absorption and onset of action for the enteric coated formulations, variability in drug absorption in different patients, difficulty in administering the formulations to patients who cannot take oral medication, pediatric and geriatric patients and possible degradation of the drug due to increased time of contact with gastric acids.
- Thus, there is a need to make a parenteral formulation of duloxetine that can overcome the disadvantages associated in the prior art. These formulations are particularly advantageous because they result in quick action and relief from pain because the drug enters systemic circulation directly bypassing first pass metabolism and gastric acid degradation.
- The present invention relates to a parenteral formulation of duloxetine comprising duloxetine dissolved in a suitable solvent system comprising one or more buffers, stabilizers and other pharmaceutically acceptable excipients. The formulation is in the form of a lyophilized injection comprising duloxetine.
-
FIG. 01 shows Permiability of various formulations evaluated using Rat Intestine at 15 minutes time (mcg/cm2). - The term “duloxetine” is intended to refer to the pharmaceutically acceptable salts, solvates and polymorphs thereof. Duloxetine Hydrochloride is most preferred.
- “Water Content” in the pharmaceutical formulation plays a major role in degrading the product. Drug gets degraded when it comes in contact with water, which ultimately effects the self-life of the product. The term “Water Content” in the present invention refers to an amount less than 5% w/w and more preferably less than 3% w/w even after 6 months of storage at accelerated conditions.
- The words “Water Content” and Moisture Content” are interchangeable and means the same throughout the specification.
- The term “lyophilize” in the context of this invention, is intended to refer to the process of freeze drying of a solution comprising duloxetine and other pharmaceutically acceptable excipients. The term “lyophilizate” refers to the product of lyophilization. The term “reconstitution” refers to dissolution of the lyophilizate for achieving a solution.
- The inventors of the present invention defined the term “parenteral” formulation, which means a pharmaceutical formulation that can be administered through intravenous, intramuscular, subcutaneous, intraperitoneal and intrathecal routes of administration.
- In one aspect, the present invention relates to a parenteral formulation of duloxetine for preoperative, peri-operative, post-operative pain management to reduce or alleviate need for Opioids and, therefore, opioid-related adverse effects or opioid-induced hyperalgesia, and for management of chronic and acute painful conditions.
- The present inventors have now surprisingly found that it is possible to make a duloxetine lyophilized formulation that would overcome the disadvantages associated with prior art.
- In one embodiment, the invention encompasses a lyophilized parenteral formulation of duloxetine.
- Lyophilization or freeze-drying is a method for dehydrating samples used to preserve or increase stability or to stop degradation. Due to the low water content of lyophilized products, the action of microorganisms and enzymes is inhibited and the product life thereby increased. In lyophilization, the sample to be lyophilized is dissolved in an aqueous solution and subsequently frozen after which the surrounding pressure is reduced. The sample is then submitted to sublimation, optionally by the application of heat, in order to sublime the frozen water directly from the solid phase to the gas phase.
- The lyophilized parenteral formulation of this invention comprises duloxetine dissolved in an aqueous vehicle and subsequently lyophilized in appropriate containers or glass vials. The lyophilizate thus formed can be reconstituted with a normal physiological solution like normal saline or with a specific diluent. The aqueous vehicle is preferably a sterile aqueous vehicle that is normally used as liquid vehicle for injection. Suitable aqueous vehicles include, for example, sterile water and sterile aqueous vehicles that contain suitable excipients that promote and preserve the stability of duloxetine after reconstitution.
- In another embodiment, the invention relates to a lyophilized formulation comprising (i) duloxetine (ii) a bulking agent, (iii) an aqueous vehicle and (iv) other pharmaceutically acceptable excipients.
- Bulking agents are used in lyophilization to increase product mass, adjust tonicity, improve product appearance, prevent product collapse, or aid in rehydration. Bulking agents for the purpose of this invention may be selected from mannitol, dextrose, cyclodextrin, sodium chloride, sorbitol and the like. Mannitol is the most preferred. The bulking agents may make up 1-99% by weight of the lyophilized solid.
- The aqueous vehicle can be selected from one or more of buffers selected from the group comprising acetate buffer, phosphate buffer, aspartic acid and boric acid buffer, citrate buffer and glycine buffer, succinate buffer, alanine buffer, valine buffer, histidine buffer, lactic acid buffer and the like. The aqueous vehicle can also contain mixture of process aid solvents like alcohols, acetonitrile, acetone and like that are removed during lyophilization.
- The inventors carried out solubility/solution stability studies to determine the solution solubility of duloxetine in various buffers at different pH values. The concentration of the solution was kept at 10 mg/ml,
-
TABLE 1 Solubility data of duloxetine in various buffers at various pH Buffer pH Observation Buffer pH Observation Phosphate 4.5 Clear solution Serine buffer 4.5 Clear solution buffer Sodium 4.5 Clear solution 5.5 Clear solution phosphate buffer Acetate 4.5 Clear solution 6.4 Clear solution buffer 5.5 Clear solution Lactic acid 4.5 Clear solution 6.4 Clear solution buffer 5.5 Clear solution 7.5 Clear solution 6.4 Clear solution Aspartic acid 4.5 Clear solution 7.5 Clear solution and Boric 5.5 Clear solution Phosphate 5.5 Insoluble acid buffer buffer Succinate 4.5 Clear solution 6.4 Insoluble buffer Glycine 4.5 Clear solution Sodium 5.5 Insoluble buffer 5.5 Clear solution phosphate 6.4 Insoluble buffer 6.4 Clear solution Citrate 4.5 Insoluble 7.5 Clear solution buffer 5.5 Insoluble Alanine 4.5 Clear solution 6.4 Insoluble buffer 5.5 Clear solution Aspartic acid 6.4 Insoluble and Boric acid buffer Valine buffer 4.5 Clear solution Succinate 5.5 Insoluble 5.5 Clear solution buffer 6.4 Insoluble 6.4 Clear solution Tris buffer 4.5 Insoluble 7.5 Clear solution 5.5 Insoluble Leucine 4.5 Clear solution 6.4 Insoluble buffer 5.5 Clear solution Alanine 6.4 Insoluble buffer 6.4 Clear solution Phenyl 6.4 Insoluble alanine buffer 7.5 Clear solution Lysine 4.5 Insoluble Isoleucine 4.5 Clear solution buffer 5.5 Insoluble buffer 5.5 Clear solution 6.4 Insoluble 6.4 Clear solution Histidine 4.5 Insoluble 7.5 Clear solution buffer 5.5 Insoluble Methionine 4.5 Clear solution 6.4 Insoluble buffer 5.5 Clear solution Tartaric acid 4.5 Insoluble 6.4 Clear solution buffer 5.5 Insoluble 7.5 Clear solution 6.4 Insoluble Proline buffer 4.5 Clear solution Meglumine 4.5 Insoluble 5.5 Clear solution buffer 5.5 Insoluble 6.4 Clear solution 6.4 Insoluble 7.5 Clear solution Serine buffer 7.5 Insoluble Phenyl alanine 4.5 Clear solution 0.1N Sodium 4.5 Insoluble buffer 5.5 Clear solution hydroxide 5.5 Insoluble Tryptophan 4.5 Clear solution buffer 6.4 Insoluble buffer 5.5 Clear solution 6.4 Clear solution 7.5 Clear solution - The solution state stability of duloxetine was studied in various buffers for 24 hours. The data is tabulated below:
-
TABLE 2 Solution state stability of duloxetine in various buffers for 24 hours Formulation Aspartic Aspartic acid + acid + Glycine Glycine Acetate Acetate Boric Acid Boric Acid Buffer Buffer Buffer Buffer Buffer Buffer (pH-5.5) (pH-6.4) (pH-5.5) (pH-6.4) (pH-5.5) (pH-6.4) Condition-RT-25° C. I* 24 h I* 24 h I* 24 h I* 24 h I* 24 h I* 24 h pH 5.59 5.5 6.23 6.35 5.32 5.4 6.38 6.1 5.8 5.7 6.6 6.5 Assay (%) 105 104.8 97.7 96.6 93.9 92.4 94.3 90.3 93.0 93.3 97.9 97.8 Total 0.12 0.2 0.10 0.18 0.14 0.2 0.1 0.1 0.3 0.5 0.3 0.5 Impurities Note: I*: Initial - The samples were stored for 24 hours and analyzed for pH, assay and total impurities by standard analytical procedures. The data showed that duloxetine has satisfactory stability in all the buffers tested. The acetate buffer at pH-5.5 and pH-6.4 and the glycine buffer at pH-5.5 and pH-6.4 showed best results in terms of assay and total impurities.
- In yet another embodiment, the invention relates to a lyophilized formulation comprising (i) duloxetine, (ii) a bulking agent, (iii) an aqueous vehicle, (iv) a stabilizer and (v) other pharmaceutically acceptable excipients.
- In yet another embodiment, the invention relates to a lyophilized formulation comprising (i) duloxetine, (ii) a bulking agent (iii) an aqueous vehicle, (iv) a stabilizer, (v) one or more pH adjusting agents and (vi) other pharmaceutically acceptable excipients.
- In yet another embodiment, the invention relates to a lyophilized formulation comprising (i) duloxetine, (ii) a bulking agent (iii) an aqueous vehicle, (iv) a stabilizer, (v) one or more surfactants and (vi) other pharmaceutically acceptable excipients.
- The lyophilized formulation of the present invention has less than 0.5% w/w of each of the following impurities: duloxetine 4-napthyl isomer ((4-[3-(Methylamino)-1-(thiophen-2-yl)propyl]naphthalen-1-ol), alpha napthol ((Naphthalen-1-01)), duloxetine beta napthol-1-yl isomer ((2-[3-(Methylamino)-1-(thiophen-2-yl)propyl]naphthalen-1-01)). More specifically the above said impurities are less than 0.3% w/w each, even after 6 months of storage under accelerated conditions.
- The stabilizer in the formulation can be selected from one or more of DOTA, DTPA, EDTA and the like. The quantity of the stabilizer can be from 0.001% w/w to 10% w/w.
- The one or more pH adjusting agents can be selected from the group comprising sodium hydroxide, hydrochloric acid, mineral acids, carboxylic acids and salts thereof.
- The surfactants may be selected from the group comprising lecithin, soya lecithin, egg lecithin, PEG-PE, phosphatidyl choline, etc
- In yet another embodiment, the invention relates to a kit comprising lyophilized formulation of duloxetine supplied together with a diluent. The diluent supplied in the kit can be selected from water for injection, dextrose solution, normal saline, mannitol solution, dextrose normal saline solution (DNS), half saline solution (with a concentration of sodium chloride at 0.45% w/v), dextrose 5%, Normal saline with Arginine (pH 10.07), Ringer Lactate solution.
- The lyophilized formulation of the present invention can be reconstituted with the diluent solution described above. It can be administered directly after reconstitution or may further be diluted with any of the physiologically acceptable solutions at the time of administration.
- The lyophilized samples prepared as per the invention were reconstituted with water and normal saline.
-
TABLE 3 Reconstitution studies of duloxetine lyophilized samples Batch Reconstituted media Initial pH Observation 1A Water 4.55 Clear solution 1B 5.56 Clear solution 1C 6.22 Clear solution 1D 4.64 Clear solution 1E 5.43 Clear solution 1F 6.11 Clear solution 1G 4.62 Clear solution 1 H 5.17 Clear solution 1I 6.02 Clear solution 1A 0.9% Sodium 4.51 Clear solution 1B chloride 5.52 Clear solution 1C 6.14 Clear solution 1D 4.63 Clear solution 1E 5.43 Clear solution 1F 6.13 Clear solution 1G 4.6 Slightly hazy 1 H 5.09 Clear solution 1I 6.07 Clear solution 316A 0.45% Sodium 6.12 Clear solution Chloride 316A Dextrose 5% 5.97 Clear solution 316A Dextrose Normal 5.77 Clear solution Saline 316A Normal saline with 7.24 Clear solution Arginine (pH 10.07) 316A Ringer Lactate 6.30 Clear solution - The formulations were observed to be clear upon reconstitution with water, 0.9% Sodium chloride, 0.45% Sodium Chloride, Dextrose 5% Dextrose Normal Saline Normal saline with Arginine (pH 10.07) Ringer Lactate.
- All the formulations showed satisfactory description and desired pH range.
- Manufacturing Process
- The subject-matter of the present invention further relates to a process for preparing the lyophilized formulation and the kit. The process comprises the steps of:
- (i) mixing the following components (in any suitable order): duloxetine or a pharmaceutically acceptable salt or solvates thereof; an aqueous vehicle; one or more bulking agents; optionally one or more stabilizers; and optionally one or more pH adjusting agents; to provide for an aqueous preparation, wherein duloxetine has a concentration of 1 to 20% w/v, based on the aqueous preparation;
- (ii) lyophilizing the aqueous preparation to provide for the lyophilized formulation in solid form; and optionally
- (iii) preparing the diluent and filling in suitable containers or vials; and optionally
- (iv) providing the lyophilized formulation and diluent in the form of a kit.
- The aqueous preparation may be a suspension/dispersion or solution. The lyophilization step may be carried out in vials, blisters or in any other larger vessel, such as stainless-steel trays or tanks, called “bulk lyophilization”.
- The bulk solution prepared in step (i) was evaluated for stability. The data is tabulated below. Stability of bulk solution is important to ensure a quality product even in the case unforeseen prolonged process times. Various concentrations of the drug i.e 10 mg/ml, 20 mg/ml and 30 mg/ml were studied in different pH ranges. The formulations were prepared as per the details of example 1.
- Stability data of bulk solution up to 24 h.
-
TABLE 4A Stability of bulk solution at a concentration of 10 mg/ml B. NO 1A 1B 1C Condition 24 h 24 h 24 h 24 h 24 h 24 h Initial 2-8° C. 25° C. Initial 2-8° C. 25° C. Initial 2-8° C. 25° C. Description Clear and Colourless Solution Assay (%) Related substances 101.9 101.9 102.0 103.4 101.4 102.0 102.4 101.9 102.4 Impurity Name % w/w Duloxetine Alcohol 0.01 0.01 0.02 ND ND ND ND ND ND Duloxetine Napthol 4-yl 0.02 0.02 0.07 0.01 0.01 0.03 0.01 0.01 0.02 isomer Alpha Napthol 0.03 0.03 0.12 0.01 0.01 0.02 0.01 0.01 0.01 Duloxetine Beta napthol- 0.02 0.02 0.07 0.01 0.01 0.04 0.01 0.01 0.02 1-yl isomer Duloxetine Related 0.05 0.05 0.05 0.06 0.06 0.06 0.06 0.06 0.04 Compound-F Total Impurities (%) 0.13 0.13 0.33 0.09 0.09 0.15 0.09 0.09 0.09 -
TABLE 4B Stability of bulk solution at a concentration of 20 mg/ml B. NO 1D 1E 1F Condition 24 h 24 h 24 h 24 h 24 h 24 h Initial 2-8° C. 25° C. Initial 2-8° C. 25° C. Initial 2-8° C. 25° C. Description Clear and Colourless Solution Assay (%) Related substances 102.1 101.4 101.8 103.2 101.2 102.1 102.7 101.2 102.0 Impurity Name % w/w Duloxetine Alcohol 0.01 0.01 0.03 ND ND 0.01 ND ND ND Duloxetine Napthol 4- 0.02 0.02 0.08 0.01 0.01 0.04 0.01 0.01 0.02 yl isomer Alpha Napthol 0.05 0.04 0.18 0.02 0.02 0.05 0.01 0.01 0.01 Duloxetine Beta 0.02 0.02 0.10 0.01 0.02 0.05 0.01 0.01 0.03 napthol-1-yl isomer Duloxetine Related 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 Compound-F Total Impurities (%) 0.16 0.15 0.46 0.10 0.11 0.21 0.09 0.09 0.12 -
TABLE 4C Stability of bulk solution at a concentration of 30 mg/ml B. NO 1G 1H 1I Condition 24 h 24 h 24 h 24 h 24 h 24 h Initial 2-8° C. 25° C. Initial 2-8° C. 25° C. Initial 2-8° C. 25° C. Description Clear and Colourless Solution Assay (%) Related substances 101.4 101.7 101.9 101.6 101.4 103.0 101.1 101.3 102.0 Impurity Name % w/w Duloxetine ND 0.01 0.03 ND ND 0.01 ND ND ND Alcohol Duloxetine 0.02 0.02 0.08 0.01 0.01 0.03 0.01 0.01 0.02 Napthol 4-yl isomer Alpha Napthol 0.03 0.03 0.16 0.01 0.01 0.05 0.01 0.01 0.02 Duloxetine Beta 0.01 0.02 0.09 0.01 0.01 0.04 0.01 0.01 0.03 napthol-1-yl isomer Duloxetine Related 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 Compound-F Total Impurities 0.12 0.14 0.42 0.09 0.09 0.19 0.09 0.09 0.13 (%) - It is evident from the data above that the stability of bulk solution is satisfactory across the pH ranges of 4.5, 5.5 and 6.4 at temperatures of 2-8° c. and 25° c. There is practically no loss in the percentage of drug after 24 hours and no increase in impurities.
- In Vitro Ex In-Vivo Permeability Study
- For administration of drug through intramuscular, subcutaneous, intraperitoneal, intrathecal, inhalation, and intranasal routes of administration, permeability of drug from the formulation plays a significant role. Thus various formulations were evaluated for permeability flux rate of Duloxetine using invitro ex-vivo rat intestine.
- Details of in-vitro and ex-vivo Permeation Study:
- a. Experimental Setup:
- 1. Permeability Barrier setup (intestine preparation):
- Wistar Rats of Body weight of 300 (+25) grams were selected and fasted overnight for 12 hours before sacrificing. The animals were sacrificed by cervical dislocation and intestinal segments (jejunum portion) were isolated. The isolated intestine segments were washed with Ringer lactate solution then stored in aerated Ringer solution till usage. 20 cms of intestine segment was selected to fill 2 mL of the sample. Both the ends of the segments were tied with cotton thread ensuring no leakage from the surface and subjected for diffusion study for determining permeability.
- 2. Sample Preparation:
- The formulation of examples of 8A, 16, 17, 6 and 18 were diluted to get concentration of 5 mg/mL of duloxetine in phosphate buffer pH 6.8. 2 mL of each solution was taken in separate.
- Wherein above examples contain: (Example 8A; soya lecithin), (Example 16; Egg Lecithin), (Example 17: HPBCD), (Example 6: PEGPE) and Duloxetine API—(Example 18))
- 3. Experimental Condition and Permeability evaluation:
- Diffusion study was performed by placing the intestine segments in 50 mL of oxygenated 6.8 pH phosphate buffer at 37±0.5° C. temperature under rotary shaking at 50 rpm. The intestine acts as donor chamber and diffusion media acts as receptor chamber from which aliquot samples were collected at predefined time points.
- 4. Sample Collection:
- The sample were collected at 15 mins, 30 mins, 45 mins, 1 Hrs, 2 Hrs, 3 Hrs, 6 Hrs, 12 Hrs, 24 Hrs and 48 Hrs. At each time point 1 mL of the sample was collected from the diffusion phase and replaced with equal volume of phosphate buffer of temperature 37±0.5° C. temperature. The samples were analysed using HPLC method for Duloxetine content.
- b. Data Evaluation:
- The samples collected at each time point were analysed for diffused drug content by HPLC method. The flux rates were calculated from slope of a trend-line plotted by taking cumulative amount drug release form unit surface area (i.e. mcg/cm2) against time (h). The flux rates were calculated using the following equation
- (1):
-
J=m/At Equation (1) - Where:
- J=is the Flux of compound “m” moving through a cross-sectional area “A” during time “t”
-
TABLE 5 Study summary Flux rate Drug conc. in the calculated Sample ID/ Description of intestinal sac/ (mcg/cm2) at S. No Details sample Volume 15th minute Remarks 1 Duloxetine API Drug dissolved in 2 mL of 5 mg/mL 16.24 Control: API in pH in pH 6.8 phosphate buffer solution (10 mg of mcg/cm2 6.8 Phosphate Phosphate buffer without any Drug in Sac) Buffer excipients 2 Duloxetine Lyophilized 2 mL of 5 mg/mL 48.21 Permeability formulation with duloxetine solution (10 mg of improved > 3 folds Soy lecithin formulation with Soy Drug in Sac) over API in buffer lecithin 3 Duloxetine Lyophilized 2 mL of 5 mg/mL 54.04 Permeability formulation with duloxetine solution (10 mg of improved > 3 folds Egg lecithin formulation with Drug in Sac) over API in buffer Egg lecithin 4 Duloxetine Lyophilized 2 mL of 5 mg/mL 38.93 Permeability formulation with duloxetine solution (10 mg of improved > 2 folds HPBCD formulation with Drug in Sac) over API in buffer HPBCD 5 Duloxetine Lyophilized 2 mL of 5 mg/mL 37.80 Permeability formulation with duloxetine solution (10 mg of improved > 2 folds PEG-PE formulation with Drug in Sac) over API in buffer PEGPE - Accompanying FIG. number 1 illustrates Permeability of various formulations evaluated using Rat Intestine at 15 minutes time (mcg/cm2). The permeability flux rate of duloxetine formulation containing Lecithin's or PEG-PE or Cyclodextrin was found to be increased by 2-3 folds than compared to flux rates of drug solution that does not have any of these excipients.
- Duloxetine Combination Formulations
- American Pain Society guidelines on management of acute pain and Chronic Non-cancer pain suggests “multimodal analgesia” or “balanced analgesia” for the treatment of postoperative pain management. Multimodal or Balanced Analgesia includes involves the use of more than one method or modality of controlling pain (e.g., drugs from two or more classes, drug plus nondrug treatment) to obtain additive beneficial effects, reduce side effects, or both.
- Nearly 50% of the patients who visit hospitals due to pain related illness suffer from acute neuropathic pain, chronic neuropathic pain, post amputation pain, cancer surgeries, post traumatic limb pain and neuropathic pain due to trauma. It would be advantageous to have a parenteral formulation with a combination of another active ingredient like paracetamol or diclofenac or the like with duloxetine that would address the treatment need in such patients. For painful phases of chronic pain management, a short duration of parenteral product usage for quick response s very much desired.
- In yet another embodiment, the invention also encompasses an injection formulation comprising (i) duloxetine or a pharmaceutically acceptable salt thereof, and (ii) a second active ingredient, selected from the group comprising paracetamol, diclofenac, gabapentin, pregabalin, dexamethasone, lidocaine, melatonin etc.
- The following Examples are intended to illustrate the present invention and are not to be considered as limiting the scope of the invention.
-
-
Quantity % w/v S. No Ingredients 1A 1B 1C 1D 1E 1 F 1 G 1 H 1 I 1. Duloxetine 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Hydrochloride 2. Mannitol 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 3. DOTA* 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 4. 5.0N Sodium 0.02 0.46 0.60 0.19 0.84 1.06 0.96 1.06 1.14 hydroxide Solution 5. Acetate buffer 84.9 84.5 84.3 84.7 84.1 83.92 84.02 83.9 83.8 (10 mg/mL) pH 4.5 5.5 6.4 4.5 5.5 6.4 4.5 5.5 6.4 *DOTA—Dodecane tetra acetic acid - Manufacturing Process
- 1. 80% of required quantity of vehicle for batch is taken in a vessel.
- 2. Duloxetine was transferred to the above vessel and dissolved by stirring at 400 rpm till the solution turned clear.
- 3. Mannitol was added to the above drug solution and stirred for 3 minutes till the solution becomes clear.
- 4. To the above solution, DOTA is added and stirred well for 1 minute till the solution turned clear.
- 5. The pH of the bulk solution is adjusted by using 5.0N Sodium hydroxide solution.
- 6. The final volume of the above solution is adjusted with remaining quantity of water for Injection.
- 7. The bulk solution is filled into vials and lyophilized.
-
-
S. No Ingredients Qty/vial (mg) Qty % w/v 1. Duloxetine Hydrochloride 56.30 3.75 2. Dextrose monohydrate 50.00 3.33 3. DOTA* 0.30 0.02 4. 0.1N Sodium hydroxide Solution 0.003 0.0002 5. Glycine solution (0.5 mg/mL) Q.s 1393.40 92.89 *DOTA—Dodecane tetra acetic acid - Manufacturing Process
- 1. 80% of required quantity of vehicle for batch is taken in a vessel.
- 2. Duloxetine was transferred to the above vessel and dissolved by stirring at 400 rpm till the solution turned clear.
- 3. Dextrose monohydrate was added to the above drug solution and stirred for 3 minutes till the solution becomes clear.
- 4. To the above solution, DOTA is added and stirred well for 1 minute till the solution turned clear.
- 5. The pH of the bulk solution is adjusted to 5.5 by using 0.1 N Sodium hydroxide Solution.
- 6. The final volume of the above solution is adjusted with remaining quantity of water for Injection.
- 7. The bulk solution is filled into vials and lyophilized.
-
-
Example 3A Example 3B Example 3C Qty/ Qty Qty/ Qty Qty/ Qty vial % Vial % vial % S. No Ingredients (mg) w/v (mg) w/v (mg) w/v 1. Duloxetine 30.0 4.0 60.0 4.0 90.0 4.0 Hydrochloride 2. Mannitol 60.0 8.0 120.0 8.0 180.0 8.0 3. DOTA* 0.15 0.02 0.3 0.02 0.45 0.02 4. 5N Sodium 6.78 0.9 13.5 0.9 20.3 0.9 hydroxide Solution 5. Acetate buffer Q.s to 87.08 Q.s to 87.08 Q.s to 87.08 (20 mg/mL) 0.75 mL 1.5 mL 2.25 mL *DOTA—Dodecane tetra acetic acid - Manufacturing Process
- 1. 80% of required total batch quantity of vehicle was dispensed and taken in a vessel.
- 2. Dispensed quantity of API was transferred to the above vessel and dissolved by stirring at 400 rpm till the solution turned clear.
- 3. Dispensed quantity of Mannitol was added to the above drug solution and stirred for 3 minutes till the solution become clear.
- 4. To the above solution dispensed quantity of stabilizer (DOTA) was added and stirred well for 1 minute till the solution turned clear.
- 5. The pH of the bulk solution was adjusted to 5.5 by using 5N Sodium hydroxide solution.
- 6. Final volume of the above solution was adjusted with remaining quantity of Vehicle.
- The formulations were studied for stability.
- Stability Study of Duloxetine Formulations
-
TABLE 6A Stability study of duloxetine formulation at 30 mg concentration B. NO 3A Condition Initial 4 W-2-8° C. 4 W-25° C. 4 W-30° C. 4 W-40° C. Strength 30 mg/vial Description White Lyophilized Powder Impurity Name % w/w Duloxetine Alcohol ND ND ND ND 0.01 Duloxetine Napthol 4-yl isomer 0.01 0.01 0.01 0.01 0.03 Alpha Napthol 0.02 0.02 0.02 0.02 0.03 Duloxetine Beta napthol-1-yl 0.01 0.01 0.02 0.02 0.06 isomer Total Impurities (%) 0.11 0.09 0.13 0.17 0.53 Assay 103.6 101.8 101.9 101.3 101.9 Water Content (mg/Vial) 4.6 4.6 6.2 14.1 7.7 Note: ND—Not determined, W—Week -
TABLE 6B Stability study of duloxetine formulation at 60 mg concentration B. NO 3B Condition Initial 4 W-2-8° C. 4 W-25° C. 4 W-30° C. 4 W-40° C. Strength 60 mg/vial Description White Lyophilized Powder Impurity Name % w/w Duloxetine Alcohol ND ND ND 0.01 0.01 Duloxetine Napthol 4-yl isomer 0.01 0.01 0.01 0.03 0.10 Alpha Napthol 0.02 0.02 0.02 0.03 0.07 Duloxetine Beta napthol-1-yl 0.01 0.01 0.02 0.06 0.28 isomer Total Impurities (%) 0.11 0.09 0.13 0.53 1.66 Assay 102.9 102.0 101.9 100.6 96.8 Water Content (mg/Vial) 9.1 8.4 11.7 10.6 10.7 Note: ND—Not determined, W—Week -
TABLE 6C Stability study of duloxetine formulation at 90 mg concentration B. NO 3C Condition Initial 4 W-2-8° C. 4 W-25° C. 4 W-30° C. 4 W-40° C. Strength 90 mg/vial Description White Lyophilized Powder Impurity Name % w/w Duloxetine Alcohol ND ND ND ND 0.01 Duloxetine Napthol 4-yl isomer 0.01 0.01 0.01 0.01 0.03 Alpha Napthol 0.02 0.02 0.02 0.02 0.03 Duloxetine Beta napthol-1-yl 0.01 0.01 0.02 0.02 0.07 isomer Total Impurities (%) 0.11 0.09 0.13 0.17 0.54 Assay 100.8 100.0 101.8 99.7 101.4 Water Content (mg/Vial) 12.5 10.8 6.2 14.1 18.5 Note: ND—Not determined, W—Week -
-
Qty/vial Qty S. No Ingredients (mg) % w/v 1. Duloxetine Hydrochloride 60.00 4.00 2. Mannitol 120.00 8.00 3. DOTA 0.30 0.02 4. Acetic acid 10.00 0.67 5. 5N Sodium hydroxide Solution 3.00 0.20 6. Glycine solution (10 mg/mL) Q.s Q.s 1.5 mL 87.11 - Manufacturing Process
- 1. 80% of required total batch quantity of glycine solution was dispensed and taken in a vessel.
- 2. Dispensed quantity of API was transferred to the above vessel and dissolved by stirring at 400 rpm till the solution turned clear.
- 3. Dispensed quantity of Mannitol was added to the above drug solution and stirred for 3 minutes till the solution become clear.
- 4. To the above solution dispensed quantity of stabilizer (DOTA/Acetic acid) was added and stirred well for 1 minute till the solution turned clear.
- 5. The pH of the bulk solution was adjusted to 5.5 by using 5N Sodium hydroxide solution.
- 6. The bulk solution was lyophilized after filling into vials
-
-
Qty/vial Quantity S. No Ingredients (mg) % w/v 1. Duloxetine Hydrochloride 60.00 4.00 2. Mannitol 120.00 8.00 3. DOTA 0.30 0.02 4. Acetic acid 10.00 0.67 5. 5N Sodium hydroxide Solution 3.00 0.20 6. Serine solution (10 mg/mL) Q.s 1.5 mL 87.94 - Manufacturing Process
- 1. 80% of required total batch quantity of Serine solution was dispensed and taken in a vessel.
- 2. Dispensed quantity of API was transferred to the above vessel and dissolved by stirring at 400 rpm till the solution turned clear.
- 3. Dispensed quantity of Mannitol was added to the above drug solution and stirred for 3 minutes till the solution become clear.
- 4. To the above solution dispensed quantity of stabilizer (DOTA/Acetic acid) was added and stirred well for 1 minute till the solution turned clear.
- 5. The pH of the bulk solution was adjusted to 5.5 by using 5N Sodium hydroxide solution.
- 6. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty S. No Ingredients (mg/mL) % w/v % w/w 1. Duloxetine Hydrochloride 30.0 3 31.40 2. Mannitol 45.0 4.5 47.10 3. EDTA 0.2 0.02 0.20 4. Lipoid PE 18:0/18:0-PEG- 10.0 1.0 10.46 2000 5. L-Histidine Q.s to Q.s to 0.34 pH 6.0 pH 6.0 6. 1% Glycine solution Q.s to 1 mL Q.s to 100% 10.46
Note: pH of the formulation: 5.5-6.5 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid PE 18:0/18:0-PEG-2000 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.0±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty S. No Ingredients (mg/mL) % w/v % w/w 1. Duloxetine Hydrochloride 30.00 3 30.864 2. Mannitol 45.00 4.5 46.296 3. EDTA 0.20 0.02 0.2058 4. Lipoid PE 18:0/18:0-PEG- 10.00 1.00 10.288 2000 5. Di-sodium succinic acid Q.s to Q.s to 2.0576 pH 6.0 pH 6.0 6. 1% Glycine solution Q.s to 1 mL Q.s to 100% 10.288
Note: pH of the formulation: 5.5-6.5 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid PE 18:0/18:0-PEG-2000 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.0±0.1 using disodium succinic acid.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Example 8A Example 8 B Qty Qty Qty Qty Qty Qty S. No Ingredients (mg/mL) % w/v % w/w (mg/mL) % w/v % w/w 1. Duloxetine 30.00 3.00 31.40 30.0 3.0 30.86 Hydrochloride 2. Mannitol 45.00 4.50 47.10 45.0 4.50 46.29 3. EDTA 0.20 0.02 0.20 0.20 0.02 0.205 4. Soy lecithin 10.00 1.00 10.468 10.0 1.00 10.28 (Lipoid S 100) 5. L-Histidine 0.32 0.03 0.34 — — — 6. Disodium — — — 2.000 0.20 2.057 Succinate 7. 1% Glycine Q.s to Q.s to 10.46 Q.s to Q.s to 10.28 solution 1 mL 100% 1 mL 100%
Note: pH of the formulation: 5.5 to 6.5 - Manufacturing Process
- Example 8A Manufacturing Process:
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid S 100 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.0±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
- Example 8B Manufacturing Process:
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid S 100 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.0±0.1 using disodium succinate.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
- The formulation made as per the composition of 8A is tested for stability. The data at the end of 6 months is tabulated below. The data clearly shows that each individual impurity is less than 0.5% even at accelerated conditions after 6 months.
-
TABLE 7 Stability data of 8A formulation. Duloxetine Hydrochloride Injection Condition Initial 6 M-2-8° C. 6 M-25° C. 6 M-30° C. 6 M-40° C. Strength 30 mg/Vial 1. Description White White White White Light Yellow lyophilized lyophilized lyophilized lyophilized color cake cake cake cake pH 6.26 6.07 5.99 5.93 5.26 Water Content NA 0.4 0.9 0.5 1.3 (mg/vial) 2. Assay (%) 104.7 104.3 100.6 101.5 102.9 3. Impurity Name Duloxetine Alcohol 0.00 ND ND ND 0.01 Duloxetine 4- 0.01 0.01 0.01 0.01 0.01 Napthyl isomer Alpha Napthol 0.00 0.01 0.02 0.02 0.06 Duloxetine Beta 0.01 0.01 0.01 0.01 0.01 napthol-1-yl isomer 4. Total Impurities 0.10 0.10 0.13 0.14 0.40 (%) -
-
Qty Qty Qty Qty S. No Ingredients (mg/5 mL) (mg/mL) % w/v % w/w 1. Duloxetine 30.00 6.00 0.60 8.54 Hydrochloride 2. Pregabalin 75.0 15.0 1.50 21.35 3. Mannitol 185 37 3.70 52.68 4. EDTA 0.20 0.04 0.004 0.05 5. Soy lecithin 10.0 2.00 0.20 2.84 (Lipoid S 100) 6. L-Histidine 0.96 0.19 0.019 0.27 7. 1% Glycine Q.s to Q.s To Q.s to 14.23 solution 5 mL 1 mL 100%
Note: pH of the formulation: 5.5-7.5 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid S 100 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of pregabalin and stirred well for 15 minutes at 400 rpm until a clear solution is obtained.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.5±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty S. No Ingredients (mg/1 mL) % w/v % w/w 1. Duloxetine 30.0 3.0 15.34 Hydrochloride 2. Gabapentin 100.0 10.0 51.14 3. Mannitol 45.00 4.50 23.01 4. EDTA 0.20 0.02 0.10 5. Soy lecithin 10.00 1.00 5.11 (Lipoid S 100) 6. L-Histidine 0.32 0.033 0.16 7. 1% Glycine solution Q.s to 1 mL Q.s to 100% 5.11
Note: pH of the formulation: 5.5-7.0 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid S 100 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of gabapentin and stirred well for 15 minutes at 400 rpm until a clear solution is obtained.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.5±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Example 11A Example 11B Qty Qty Qty Qty Qty Qty Qty Qty (mg/ (mg/ % % (mg/ (mg/ % % S. No Ingredients 20 mL) mL) w/v w/w 20 mL) mL) w/v w/w 1. Duloxetine 30.00 1.50 0.30 2.66 30.00 1.50 0.30 3.22 Hydrochloride 2. Dexamethasone 8.00 0.40 0.08 0.711 12.00 0.60 0.12 1.29 sodium phosphate 3. Mannitol 875.00 43.75 4.37 77.74 875.00 43.75 4.37 94.10 4. EDTA 0.20 0.01 0.002 0.017 0.20 0.01 0.002 0.021 5. Soy lecithin 10.00 0.50 0.10 0.88 10.0 0.50 0.10 1.075 (Lipoid S 100) 6. L-Histidine 2.36 0.118 0.011 0.20 2.59 0.12 0.012 0.27 7. 1% Glycine Q.s to Q.s. to Q.s to 17.768 Q.s to Q.s. to Q.s to 3.22 solution 20 mL 1 mL 100% 10 mL 1 mL 100%
Note: pH of the formulation: 7.5-8.5 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid S 100 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of dexamethasone sodium phosphate and stirred well for 45 minutes at 400 rpm until a clear solution is obtained.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 7.8±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty Qty S. No Ingredients (mg/25 mL) (mg/mL) % w/v % w/w 1. Duloxetine 30.00 1.20 0.12 2.39 Hydrochloride 2. Diclofenac 37.50 1.50 0.15 2.99 Sodium 3. Mannitol 920.00 36.80 3.68 73.36 4. EDTA 0.20 0.01 0.001 0.019 5. Soy lecithin 10.00 0.40 0.04 0.79 (Lipoid S 100) 6. L-Histidine 6.24 0.24 0.024 0.49 7. 1% Glycine Q.s to Q.s. to Q.s to 19.936 solution 25 mL 1 mL 100%
Note: pH of the formulation: 5.5-7.5 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid S 100 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of Diclofenac Sodium and stirred well for 45 minutes at 400 rpm until a clear solution is obtained.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.5±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty Qty S. No Ingredients (mg/50 mL) (mg/mL) % w/v % w/w 1. Duloxetine 30.00 0.60 0.060 1.0375 Hydrochloride 2. Paracetamol 500.00 10.00 1.000 17.291 3. Mannitol 1835.00 36.70 3.670 63.46 4. EDTA 0.20 0.00 0.000 0.0069 5. Soy lecithin 10.00 0.20 0.020 0.346 (Lipoid S 100) 6. L-Histidine 16.4 0.328 0.0328 0.567 7. 1% Glycine Q.s to Q.s. to Q.s to 100% 17.29 solution 50 mL 1 mL
Note: pH of the formulation: 5.5-6.5 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid S 100 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of paracetamol and stirred well for 60 minutes at 400 rpm until a clear solution is obtained.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.0±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty S. No Ingredients (mg/mL) % w/v (w/w) 1. Duloxetine 30.00 3 15.343 Hydrochloride 2. Lidocaine HCl 100.00 10 51.143 3. Mannitol 45.00 4.5 23.015 4. EDTA 0.20 0.02 0.1023 5. Lipoid PE 18:0/ 10.00 1.00 5.1144 18:0-PEG-2000 6. L-Histidine Q.s to pH 6.0 Q.s to pH 6.0 0.168 7. 1% Glycine Q.s to 1 mL Q.s to 100% 5.12 solution
Note: pH of the formulation: 5.5-6.5 - Manufacturing Process
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid PE 18:0/18:0-PEG-2000 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of lidocaine hydrochloride and stirred well for 30 minutes at 400 rpm until a clear solution is obtained.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.0±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty S. No Ingredients (mg/mL) % w/v % w/w 1. Duloxetine 30.00 3 15.21 Hydrochloride 2. Lidocaine HCl 100.0 10 50.71 3. Mannitol 45.0 4.5 22.8 4. EDTA 0.20 0.02 0.10 5. Lipoid PE 18:0/ 10.0 1.0 5.07 18:0-PEG-2000 6. Di-sodium succinic Q.s to pH 6.0 Q.s to pH 6.0 1.01 acid 7. 1% Glycine Q.s to 1 mL Q.s to 100% 5.07 solution
Note: pH of the formulation: 5.5-6.5 - Manufacturing Procedure
- 1. Preparation of 1% Glycine solution: Required quantity of ultrapure water was taken in a stainless steel vessel to which desired quantity of Glycine was added to get 1% w/v solution.
- 2. Preparation of Bulk solution: 80% of glycine solution required was taken in a manufacturing vessel to which dispensed quantity of Lipoid PE 18:0/18:0-PEG-2000 was transferred and stirred for 15 minutes at 450 rpm to obtain a clear solution.
- 3. To the above solution dispensed quantity of duloxetine was added and stirred for 30 minutes at 400 rpm for obtaining a clear solution, followed by addition of Lidocaine hydrochloride and stirred well for 30 minutes at 400 rpm until a clear solution is obtained.
- 4. Dispensed quantity of Mannitol was added to the above solution and stirred for 30 minutes at 400 rpm to get a clear solution.
- 5. Required quantity of EDTA was transferred to the manufacturing vessel and stirred for 15 minutes at 400 rpm to get clear solution.
- 6. pH of the above bulk solution was adjusted to pH 6.0±0.1 using disodium succinic acid.
- 7. Final volume of the bulk solution was adjusted to desired level with remaining amount of 1% glycine solution.
- 8. The bulk solution was lyophilized after filling into vials.
-
-
Qty Qty Qty S. No Ingredients (mg/mL) % w/v % w/w 1. Duloxetine 30.00 3.00 31.40 Hydrochloride 2. Mannitol 45.00 4.50 47.10 3. EDTA 0.20 0.02 0.20 4. Egg lecithin 10.00 1.00 10.46 (Lipoid E80S) 5. L-Histidine 0.32 0.03 0.34 6. 1% Glycine Q.s to 1 mL Q.s to 100% 10.46 solution - Manufacturing Process
- 1. Preparation of 1% glycine solution: Required quantity of glycine was dissolved in required quantity of water.
- 2. Preparation of Bulk solution: 80% of glycine solution required for the batch was taken in a manufacturing vessel to which required quantity of Lipoid E80S was transferred and stirred to obtain a clear solution.
- 3. To the above solution required quantity of duloxetine was added and stirred to get clear solution.
- 4. Required quantity of Mannitol was added to the above solution and stirred to get a clear solution.
- 5. Required quantity of EDTA was transferred to the above solution and stirred to get clear solution.
- 6. pH of the above bulk solution adjusted to pH 6.0±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted with remaining amount of 1% glycine solution.
- 8. The bulk solution was filtered and filled into vials and were then partially stoppered with single slotted lyo stopper and subjected for lyophilisation.
- 9. After lyophilisation the vials were stoppered completely under vacuum and were sealed with aluminium tear off seals after unloading.
-
-
Qty Qty Qty S. No Ingredients (mg/mL) % w/v % w/w 1. Duloxetine 30.00 3.00 31.40 Hydrochloride 2. Mannitol 45.00 4.50 47.10 3. EDTA 0.20 0.02 0.20 4. HPBCD 10.00 1.00 10.46 (Hydroxypropyl Beta cyclodextrin) 5. L-Histidine 0.32 0.03 0.34 6. 1% Glycine Q.s to 1 mL Q.s to 100% 10.46 solution - Manufacturing Process
- 1. Preparation of 1% glycine Solution: Required quantity of glycine was dissolved in required quantity of water.
- 2. Preparation of Bulk Solution: 80% of glycine solution required for the batch was taken in a manufacturing vessel to which required quantity of HPBCD was transferred and stirred obtain a clear solution.
- 3. To the above solution required quantity of duloxetine was added and stirred to get clear solution.
- 4. Required quantity of Mannitol was added to the above solution and stirred to get a clear solution.
- 5. Required quantity of EDTA was transferred to the above solution and stirred to get clear solution.
- 6. pH of the above bulk solution adjusted to pH 6.0±0.1 using L-histidine.
- 7. Final volume of the bulk solution was adjusted with remaining amount of 1% glycine solution.
- 8. The bulk solution was filtered and filled into vials and were then partially stoppered with single slotted lyo stopper and subjected for lyophilisation.
- 9. After lyophilisation the vials were stoppered completely under vacuum and were sealed with aluminium tear off seals after unloading.
-
-
Qty Qty Qty S. No Material name (mg/mL) % w/v % w/w 1. Duloxetine 30.00 3.00 2.94 Hydrochloride 2. Phosphate Buffer Q.s to 1 mL Q.s to 100% 97.06 pH 6.8 - Manufacturing Process
- 1. 80% of Phosphate buffer pH 6.8 required for the batch was taken in a SS vessel.
- 2. Required quantity of Duloxetine API was dispensed and transferred to the above vessel and dissolved with stirring for 10 minutes at 300 rpm.
- 3. Ensuring the clarity of the solution the volume was adjusted with remaining amount of Phosphate buffer.
Claims (10)
1. A parenteral formulation comprising lyophilized duloxetine or a pharmaceutically acceptable salt thereof, optionally together with one or more pharmaceutically acceptable excipients.
2. The formulation of claim 1 , wherein the moisture content of the lyophilized cake is less than 5% w/w.
3. The formulation of claim 1 , wherein the content of Duloxetine Alcohol, Duloxetine Napthol 4-yl isomer, Alpha Napthol and Duloxetine Beta napthol-1-yl isomer individually is less than 0.5% w/w.
4. The formulation of claim 1 , wherein the pharmaceutically acceptable excipients are selected from the group comprising bulking agents, aqueous vehicle, stabilizers, and surfactants.
5. The formulation of claim 4 , wherein the bulking agents are selected from mannitol, dextrose, cyclodextrin, sodium chloride and sorbitol.
6. The formulation of claim 4 , wherein the aqueous vehicle is selected from one or more buffers selected from the group comprising acetate buffer, phosphate buffer, aspartic acid and boric acid buffer, citrate buffer and glycine buffer, histidine buffer, succinate buffer, alanine buffer, valine buffer, lactic acid buffer.
7. The formulation of claim 4 , wherein the surfactant is selected from the group comprising lecithin, soya lecithin, egg lecithin, PEG-PE and phosphatidyl choline.
8. A kit comprising (i) a vial comprising lyophilized duloxetine, optionally with pharmaceutically acceptable excipients and (ii) a vial comprising a diluent
9. The kit of claim 8 wherein the diluent is selected from the group comprising water for injection, dextrose solution, normal saline, mannitol solution, dextrose normal saline solution, half saline solution.
10. The kit of claim 8 , wherein the pH of the reconstituted solution is between 4-8.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201941047735 | 2019-11-22 | ||
IN201941047735 | 2019-11-22 | ||
PCT/IB2020/061263 WO2021100030A1 (en) | 2019-11-22 | 2020-11-30 | Stable parenteral formulations of duloxetine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2020/061263 A-371-Of-International WO2021100030A1 (en) | 2019-11-22 | 2020-11-30 | Stable parenteral formulations of duloxetine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/386,863 Continuation US20240058272A1 (en) | 2019-11-22 | 2023-11-03 | Stable parenteral formulations of duloxetine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220409544A1 true US20220409544A1 (en) | 2022-12-29 |
Family
ID=75981170
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/778,906 Pending US20220409544A1 (en) | 2019-11-22 | 2020-11-30 | Stable parenteral formulations of duloxetine |
US18/386,863 Pending US20240058272A1 (en) | 2019-11-22 | 2023-11-03 | Stable parenteral formulations of duloxetine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/386,863 Pending US20240058272A1 (en) | 2019-11-22 | 2023-11-03 | Stable parenteral formulations of duloxetine |
Country Status (6)
Country | Link |
---|---|
US (2) | US20220409544A1 (en) |
EP (1) | EP4057992A1 (en) |
AU (1) | AU2020385714A1 (en) |
MX (1) | MX2022006085A (en) |
WO (1) | WO2021100030A1 (en) |
ZA (1) | ZA202206250B (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100335122C (en) * | 1999-03-03 | 2007-09-05 | 伊莱利利公司 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
US8153824B2 (en) * | 2005-06-22 | 2012-04-10 | The Wockhardt Company | Antidepressant oral liquid compositions |
BR112020005703A2 (en) * | 2017-09-27 | 2020-10-20 | Novartis Ag | parenteral formulation comprising siponimod |
-
2020
- 2020-11-30 US US17/778,906 patent/US20220409544A1/en active Pending
- 2020-11-30 MX MX2022006085A patent/MX2022006085A/en unknown
- 2020-11-30 WO PCT/IB2020/061263 patent/WO2021100030A1/en active Application Filing
- 2020-11-30 AU AU2020385714A patent/AU2020385714A1/en active Pending
- 2020-11-30 EP EP20891272.5A patent/EP4057992A1/en active Pending
-
2022
- 2022-06-06 ZA ZA2022/06250A patent/ZA202206250B/en unknown
-
2023
- 2023-11-03 US US18/386,863 patent/US20240058272A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021100030A1 (en) | 2021-05-27 |
EP4057992A1 (en) | 2022-09-21 |
ZA202206250B (en) | 2023-02-22 |
US20240058272A1 (en) | 2024-02-22 |
AU2020385714A1 (en) | 2022-06-09 |
MX2022006085A (en) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102558716B1 (en) | Single-dose, ready-to-use injectable formulation | |
JP6612200B2 (en) | Choline salts of anti-inflammatory substituted cyclobutenedione compounds | |
US10201519B2 (en) | Stabilized pediatric suspension of carisbamate | |
ES2645588T3 (en) | Methods and compositions for oral administration of exenatide | |
EP2299987B1 (en) | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | |
US20080103121A1 (en) | Cephalosporin derivative formulation | |
JP7306718B2 (en) | Lipid-based nanoparticles with improved stability | |
JP2018528242A (en) | Process for producing stable therapeutic glucagon formulations in aprotic polar solvents | |
CN116367837A (en) | Formulations of antiviral compounds | |
JP2004510816A (en) | Pharmaceutical solutions of modafinil compounds | |
WO2008091177A1 (en) | Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes | |
CA2977168C (en) | Enteric-coated pellets containing a proton pump inhibitor | |
NZ539046A (en) | Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability | |
JPH11507936A (en) | Lamotrigine-containing pharmaceutical composition | |
US20170281607A1 (en) | Pharmaceutical compositions and methods for the treatment of diabetes | |
JP2016533317A (en) | Preventive and / or therapeutic drug for polycystic kidney disease | |
AU2021269450A1 (en) | Parenteral Formulation comprising Siponimod | |
US20220409544A1 (en) | Stable parenteral formulations of duloxetine | |
US20230330079A1 (en) | Orally-disintegrating film comprising naratriptan | |
TWI821541B (en) | Oral formulation and treatment of pth analog | |
JP7146281B2 (en) | Pharmaceutical composition for nasal administration | |
JP5845183B2 (en) | Formulation containing triptan compound | |
JP2022533510A (en) | Orally disintegrating tablets containing glycopyrrolate and methods for increasing bioavailability | |
KR20200087138A (en) | Sustained-release formulation for intra-articular application | |
US20210369615A1 (en) | Solid oral formulations of amphotericin b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |